$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2015 Q1 Form 10-Q Financial Statement

#000119312515175515 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.170M $3.060M
YoY Change -29.08% 29.66%
% of Gross Profit
Research & Development $2.448M $1.158M
YoY Change 111.46% 56.36%
% of Gross Profit
Depreciation & Amortization $3.189K $1.716K
YoY Change 85.84% 10.71%
% of Gross Profit
Operating Expenses $4.620M $4.382M
YoY Change 5.43% 491.75%
Operating Profit -$4.620M -$4.382M
YoY Change 5.45% 34.94%
Interest Expense $100.0K -$2.290M
YoY Change -104.37% 148.91%
% of Operating Profit
Other Income/Expense, Net $95.00K -$2.285M
YoY Change -104.16% 147.56%
Pretax Income -$4.530M -$6.670M
YoY Change -32.08% 59.95%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.525M -$6.667M
YoY Change -32.13% 59.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$24.46K -$39.50K
COMMON SHARES
Basic Shares Outstanding 186.0M shares 173.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.17M $16.65M
YoY Change -14.89% 285.42%
Cash & Equivalents $14.17M $16.65M
Short-Term Investments
Other Short-Term Assets $1.224M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.86M $16.65M
YoY Change -4.73% 273.29%
LONG-TERM ASSETS
Property, Plant & Equipment $88.98K $28.40K
YoY Change 213.35% -5.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K
YoY Change 0.0% -10.0%
Total Long-Term Assets $6.910M $4.142M
YoY Change 66.82% -13.88%
TOTAL ASSETS
Total Short-Term Assets $15.86M $16.65M
Total Long-Term Assets $6.910M $4.142M
Total Assets $22.77M $20.79M
YoY Change 9.52% 124.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $650.0K $730.0K
YoY Change -10.96% 1360.0%
Accrued Expenses $370.0K $110.0K
YoY Change 236.36% -54.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.022M $835.2K
YoY Change 22.43% 187.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K $5.440M
YoY Change -99.08% 54.55%
Total Long-Term Liabilities $50.00K $5.440M
YoY Change -99.08% 54.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.022M $835.2K
Total Long-Term Liabilities $50.00K $5.440M
Total Liabilities $1.075M $6.271M
YoY Change -82.86% 64.17%
SHAREHOLDERS EQUITY
Retained Earnings -$160.8M -$152.7M
YoY Change 5.3%
Common Stock $186.0K $173.1K
YoY Change 7.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.70M $14.52M
YoY Change
Total Liabilities & Shareholders Equity $22.77M $20.79M
YoY Change 9.52% 124.29%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$4.525M -$6.667M
YoY Change -32.13% 59.88%
Depreciation, Depletion And Amortization $3.189K $1.716K
YoY Change 85.84% 10.71%
Cash From Operating Activities -$4.190M -$2.851M
YoY Change 46.98% -4.22%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 970.0K 3.803M
YoY Change -74.5% -37.37%
NET CHANGE
Cash From Operating Activities -4.190M -2.851M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 970.0K 3.803M
Net Change In Cash -3.220M 952.7K
YoY Change -438.0% -69.23%
FREE CASH FLOW
Cash From Operating Activities -$4.190M -$2.851M
Capital Expenditures $0.00
Free Cash Flow -$2.851M
YoY Change -4.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
33334 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3036218 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16648916
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185972159 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185972159 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
185972159 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
441052
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1022439
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
185972
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160818917
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
21696349
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
278656
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22771322
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8299517
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
182329294
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91282
CY2015Q1 us-gaap Liabilities
Liabilities
1074973
CY2015Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
652501
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14170733
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88982
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3415928
CY2015Q1 us-gaap Assets
Assets
22771322
CY2015Q1 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3378345
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1223668
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
15861067
CY2015Q1 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
466666
CY2015Q1 pvct Warrant Liability
WarrantLiability
52534
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15696243
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184796275 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184796275 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
437863
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
847722
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
184796
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156293810
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
25189876
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
315738
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26184158
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8131737
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181298890
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91282
CY2014Q4 us-gaap Liabilities
Liabilities
994282
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
440702
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92171
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3583708
CY2014Q4 us-gaap Assets
Assets
26184158
CY2014Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3378345
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
978000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19102934
CY2014Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
733333
CY2014Q4 pvct Warrant Liability
WarrantLiability
146560
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
CY2014Q1 pvct Convertible Preferred Stock Shares To Be Converted To Common Stock Shares
ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares
33334 shares
CY2014 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2850713
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
168859658 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4381607
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-6667267
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1373
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1157883
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
952673
CY2014Q1 us-gaap Depreciation
Depreciation
1716
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3803386
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-54211
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
900317
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3055944
CY2014Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
376419
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
121500 shares
CY2014Q1 pvct Gain Loss On Fair Value Of Warrant Liability
GainLossOnFairValueOfWarrantLiability
-2287033
CY2014Q1 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
-2287033
CY2014Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
-1153835
CY2014Q1 pvct Warrants Exercised On Cashless Basis
WarrantsExercisedOnCashlessBasis
12522198 shares
CY2014Q1 pvct Aggregate Exercise Price Of Warrants Exercised
AggregateExercisePriceOfWarrantsExercised
2672364
CY2014Q1 pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
3803386
CY2014Q1 pvct Amount Reclassified From Warrant Liability To Equity
AmountReclassifiedFromWarrantLiabilityToEquity
9717549
CY2014Q1 pvct Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
3036218 shares
CY2014Q1 pvct Issuance Of Stock For Services
IssuanceOfStockForServices
137500
CY2014Q1 pvct Stock Issued During Period Shares Warrants Exercised On Cashless Basis
StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis
9100824 shares
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
733000 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
CY2015Q1 dei Trading Symbol
TradingSymbol
PVCT
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> 2. <b>Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations.&#xA0;The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company&#x2019;s prescription drug candidates, or sell or license the Company&#x2019;s OTC products or non-core technologies.</p> </div>
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4186816
CY2015Q1 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
776000 shares
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185196323 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000315545
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-266667
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4620471
CY2015Q1 us-gaap Revenues
Revenues
0
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4525107
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1338
CY2015Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
64000
CY2015Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
245668
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2280706
CY2015Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3220868
CY2015Q1 us-gaap Depreciation
Depreciation
3189
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
965948
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-37082
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2171985
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
211799
CY2015Q1 pvct Gross Proceeds From Sales Of Common Stock And Warrants
GrossProceedsFromSalesOfCommonStockAndWarrants
776000
CY2015Q1 pvct Purchase Price Of Common Stock With Warrants
PurchasePriceOfCommonStockWithWarrants
1.00
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
3693898 shares
CY2015Q1 pvct Gain Loss On Fair Value Of Warrant Liability
GainLossOnFairValueOfWarrantLiability
94026
CY2015Q1 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
94026
CY2015Q1 pvct Stock Issued During Period Warrants And Stock Options Exercised Value
StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue
290828
CY2015Q1 pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The cash settlement amounts will be repaid to the Company over a period of five years with the first payment due in October 2015 and the final payment is expected to be received by October 3, 2019.
CY2015Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
14275
CY2015Q1 pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
675120
CY2015Q1 pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
CY2015Q1 pvct Warrant Issued During Period For Services Value
WarrantIssuedDuringPeriodForServicesValue
1632
CY2015Q1 pvct Issuance Of Stock For Services
IssuanceOfStockForServices
64000
CY2015Q1 pvct Percentage Of Common Shares Issuable On Exercise Of Each Warrant
PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant
0.50 pure
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Issuance Of Common Stock And Warrants Pursuant To Regulation D Value
IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue
675120

Files In Submission

Name View Source Status
0001193125-15-175515-index-headers.html Edgar Link pending
0001193125-15-175515-index.html Edgar Link pending
0001193125-15-175515.txt Edgar Link pending
0001193125-15-175515-xbrl.zip Edgar Link pending
d907246d10q.htm Edgar Link pending
d907246dex311.htm Edgar Link pending
d907246dex312.htm Edgar Link pending
d907246dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pvct-20150331.xml Edgar Link completed
pvct-20150331.xsd Edgar Link pending
pvct-20150331_cal.xml Edgar Link unprocessable
pvct-20150331_def.xml Edgar Link unprocessable
pvct-20150331_lab.xml Edgar Link unprocessable
pvct-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending